SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology – Activating Antigen Carriers (AACs)
Preclinical data demonstrate SQZ AACs ability to prime antigen-specific T cell responses and drive tumor reduction in vivo
SQZ to also present additional preclinical data on company’s first oncology approach with SQZPBMC-HPV
WATERTOWN, Mass., Nov. 5, 2019 — SQZ Biotechnologies (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the first data highlighting the potential of the company’s activating antigen carrier (AAC) immunotherapy program for oncology indications. The findings will be detailed in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. SQZ AACs are part of SQZ’s immune-oncology pipeline, which also includes SQZ Antigen Presenting Cells (APCs).
SQZ Biotech Announces Clearance of US IND Application for First Clinical Trial
First program advancing into the clinic through the SQZ-Roche collaboration in APCs for oncology
WATERTOWN, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) — SQZ Biotechnologies (SQZ), a cell therapy company developing innovative treatments for multiple therapeutic areas, today announced that the company’s Investigational New Drug (IND) application for SQZ-PBMC-HPV, a novel cellular immunotherapy of antigen presenting cells (APCs) has been cleared after submission to the U.S. Food and Drug Administration (FDA).
Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the BoardBEDFORD Mass., October 21, 2019 — Verseau Therapeutics, Inc. (“Verseau”) launched today with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital.
Corindus Vascular Robotics Announces Definitive Agreement to be Acquired by Siemens Healthineers
WALTHAM, Mass., — August 8, 2019 — Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggregate purchase price of approximately $1.1 billion.